Category: Biotechnology
Global Biotechnology
-
Biobanks
... 7.7% over the analysis period 2024-2030. Physical / Real, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$108.4 Billion by the end of the analysis period. ... Read More
-
Mesenchymal Stem Cells (MSC)
... 2030, growing at a CAGR of 12.2% over the analysis period 2024-2030. Bone Marrow, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$3.4 Billion by the ... Read More
-
Predictive Diagnostics
... CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$821.4 Million While China is Forecast to Grow at 9.9% CAGR The Predictive Diagnostics market in the U.S. is estimated at ... Read More
-
Circulating Tumor Cell (CTC) Diagnostics
... Billion by 2030, growing at a CAGR of 11.1% over the analysis period 2024-2030. Detection & Enrichment, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$15.4 ... Read More
-
Personalized Medicines
... CAGR of 4.6% over the analysis period 2024-2030. Personalized Nutrition & Wellness, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$484.0 Billion by the end of ... Read More
-
Microbiome Sequencing Services
... at a CAGR of 18.2% over the analysis period 2024-2030. Synthesis, one of the segments analyzed in the report, is expected to record a 16.8% CAGR and reach US$2.3 Billion by the end of the ... Read More
-
Allogeneic Stem Cells
... at a CAGR of 10.9% over the analysis period 2024-2030. Regenerative Therapy, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.6 Billion by the end of ... Read More
-
Next Generation Sequencers
... at a CAGR of 17.3% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 17.1% CAGR and reach US$26.6 Billion by the end of the ... Read More
-
Biomarkers
... 13.7% over the analysis period 2024-2030. Safety, one of the segments analyzed in the report, is expected to record a 13.9% CAGR and reach US$89.8 Billion by the end of the analysis period. Growth in ... Read More
-
Intravenous Immunoglobulin (IVIg)
... at a CAGR of 8.5% over the analysis period 2024-2030. IgA, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$13.7 Billion by the end of the ... Read More
-
Microplate Systems
... CAGR of 4.6% over the analysis period 2024-2030. Readers, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$851.2 Million by the end of the analysis period. ... Read More
-
Antimicrobial Susceptibility Testing
... at a CAGR of 3.4% over the analysis period 2024-2030. Manual Products, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$1.5 Billion by the end of ... Read More
-
In Situ Hybridization (ISH)
... 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Fluorescence In Situ Hybridization (FISH), one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$1.1 ... Read More
-
microRNA (miRNA)
... CAGR of 13.1% over the analysis period 2024-2030. Products, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$411.8 Million by the end of the analysis period. ... Read More
-
Cell Analysis
... CAGR of 5.5% over the analysis period 2024-2030. Flow Cytometry Products, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$10.3 Billion by the end of the ... Read More
-
Gene Therapy
... CAGR of 23.0% over the analysis period 2024-2030. Viral, one of the segments analyzed in the report, is expected to record a 23.3% CAGR and reach US$5.5 Billion by the end of the analysis period. ... Read More
-
Gene Amplification Technologies
... at a CAGR of 10.0% over the analysis period 2024-2030. Medical & Pharma, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$6.4 Billion by the end ... Read More
-
Starch
... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Liquid Starch, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach 118.1 Million Metric Tons ... Read More
-
Protein Ingredients
... CAGR of 7.1% over the analysis period 2024-2030. Egg, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$35.2 Billion by the end of the analysis period. ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Biotechnology Instrumentation
... CAGR of 5.4% over the analysis period 2024-2030. Immunoassay Systems, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$26.1 Billion by the end of the analysis ... Read More
-
Biotechnology Reagents
... CAGR of 4.4% over the analysis period 2024-2030. Chromatography, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$40.6 Billion by the end of the analysis period. ... Read More
-
Animal Feed Additives
... at a CAGR of 5.4% over the analysis period 2024-2030. Amino Acids, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$20.7 Billion by the end of ... Read More
-
Immunochemicals
... 5.1% over the analysis period 2024-2030. Catalog Antibodies, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth ... Read More
-
Epigenetics
... 18.2% over the analysis period 2024-2030. Epigenetics Kits, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth ... Read More
Research Assistance
